| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥83.0B | ¥70.6B | +17.5% |
| Operating Income | ¥6.2B | ¥-1.8B | +436.4% |
| Ordinary Income | ¥6.8B | ¥-1.2B | +690.5% |
| Net Income | ¥6.0B | ¥-0.8B | +883.1% |
| ROE | 5.5% | -0.7% | - |
FY2026 Q3 consolidated results: Revenue ¥83.0B (YoY +17.5%), Operating Income ¥6.2B (YoY +436.4%, prior period loss ¥-1.8B), Ordinary Income ¥6.8B (YoY +690.5%, prior period loss ¥-1.2B), Net Income ¥6.0B (YoY +883.1%, prior period loss ¥-0.8B). The company achieved a turnaround from operating loss to profit, marking a significant inflection point. Revenue growth was driven by expansion across all three business segments, with FineChemical leading at ¥39.0B and FlameRetardants contributing ¥33.1B. Gross profit margin improved to 23.4% from prior period's approximately 16.8%, while operating margin reached 7.5% compared to negative territory in the prior period. This represents the company's first profitable quarter following consecutive periods of losses, demonstrating structural recovery in core operations.
Revenue increased ¥12.4B (+17.5%) to ¥83.0B, with all three segments contributing to growth. FineChemical segment revenue grew ¥9.54B (+32.3%) to ¥39.0B, representing 47.0% of total revenue and establishing itself as the largest revenue contributor. FlameRetardants segment increased ¥2.50B (+8.2%) to ¥33.1B, accounting for 39.9% of total revenue. HealthSupport segment grew ¥0.31B (+3.0%) to ¥10.8B, representing 13.0% of total revenue. The revenue expansion was accompanied by significant margin improvement across the organization.
Operating income turned positive at ¥6.2B from prior period loss of ¥-1.8B, representing a swing of ¥8.0B. This improvement was driven by segment-level profitability gains and gross margin expansion. Cost of sales increased ¥9.8B to ¥63.6B, but at a slower rate than revenue growth, resulting in gross profit expansion of ¥2.6B to ¥19.4B. Gross profit margin improved 6.6 percentage points to 23.4%. SG&A expenses increased ¥0.2B (+1.5%) to ¥13.2B, demonstrating cost discipline as the SG&A ratio declined to 15.9% from 18.5% in the prior period. The combination of revenue scale-up and operational leverage drove operating margin improvement to 7.5% from negative 2.6%.
Non-operating items contributed a net positive ¥0.6B, with non-operating income of ¥0.9B exceeding non-operating expenses of ¥0.2B. Foreign exchange effects were mixed, with FX losses of ¥0.2B in non-operating expenses offsetting gains elsewhere. Ordinary income reached ¥6.8B, representing a 9.6% increase over operating income, indicating balanced non-operating activities. Extraordinary items added ¥0.8B to profit, primarily from gain on sale of assets of ¥0.1B and other non-recurring gains. The gap between ordinary income of ¥6.8B and net income of ¥6.0B reflects income tax expense of ¥1.7B, representing an effective tax rate of 22.1% on profit before tax of ¥7.7B.
This quarter exemplifies a revenue up/profit up pattern, characterized by strong top-line growth accompanied by significant operating leverage effects and return to profitability across all income statement levels. The turnaround was fundamentally driven by segment operational improvements rather than solely non-recurring factors, though extraordinary gains of ¥0.8B provided additional lift to net income.
FineChemical segment generated revenue of ¥39.0B with operating income of ¥9.6B, yielding a segment margin of 24.6%. This represents the highest profitability segment and the largest contributor to consolidated operating income, with segment profit increasing ¥4.67B from prior period's ¥4.94B. The segment's strong margin reflects premium product positioning and operational efficiency, establishing FineChemical as the core profit engine of the company.
FlameRetardants segment recorded revenue of ¥33.1B with operating income of ¥3.8B, resulting in a segment margin of 11.5%. Segment profit improved ¥3.02B from prior period's ¥0.78B, demonstrating significant operational recovery. While margins trail FineChemical by 13.1 percentage points, the segment's substantial revenue base and improving profitability make it an important contributor to consolidated results.
HealthSupport segment achieved revenue of ¥10.8B with operating income of ¥0.9B, yielding a segment margin of 8.0%. Segment profit increased ¥0.46B from prior period's ¥0.41B. This represents the smallest segment by both revenue (13.0% share) and profitability, with the lowest margin among the three segments. The margin differential of 16.6 percentage points versus FineChemical indicates either earlier-stage business development or more competitive market dynamics.
Corporate expenses not allocated to segments totaled ¥8.1B, representing overhead costs for administrative functions. After adjusting for these unallocated costs, total segment profit of ¥14.3B reconciles to consolidated operating income of ¥6.2B. The ratio of corporate costs to segment profit stands at 56.6%, suggesting meaningful opportunity for leverage improvement as segment profits scale.
[Profitability] ROE of 5.5% reflects the company's return to profitability but remains below the industry median of 5.8%, indicating room for improvement relative to peers. Operating margin of 7.5% improved substantially from prior period losses but trails the industry median of 8.9% by 1.4 percentage points. Net profit margin of 7.3% exceeds the industry median of 6.5% by 0.8 percentage points, suggesting effective cost management and tax efficiency. The company's DuPont decomposition reveals ROE of 5.5% driven by net profit margin of 7.3%, asset turnover of 0.574, and financial leverage of 1.31. Segment-level margins span a wide range from 24.6% in FineChemical to 8.0% in HealthSupport, highlighting the importance of portfolio mix on consolidated profitability. [Cash Quality] Cash and deposits of ¥34.0B provide substantial liquidity coverage, representing 1.25 times short-term liabilities and 30.7% of total assets. Interest coverage ratio stands at approximately 619 times based on operating income of ¥6.2B versus minimal interest expense, indicating negligible debt servicing burden. The cash conversion quality warrants attention, as accounts receivable of ¥25.2B and inventories of ¥21.1B represent significant working capital tied up in operations. [Investment Efficiency] Total asset turnover of 0.574 times matches the industry median of 0.56, indicating average capital efficiency relative to peers. Return on assets of 4.2% (net income ¥6.0B / total assets ¥144.6B) slightly exceeds the industry median of 3.4%, reflecting improved profitability offsetting capital intensity. Fixed asset intensity increased with property, plant and equipment rising to ¥26.6B, driven primarily by construction in progress of ¥7.7B, signaling ongoing capital deployment. [Financial Health] Equity ratio of 76.5% substantially exceeds the industry median of 63.8%, positioning the company in the upper quartile for financial stability. Current ratio of 361.5% far exceeds the industry median of 287%, demonstrating exceptional short-term liquidity. Debt-to-equity ratio of 0.04 based on interest-bearing debt of ¥4.3B versus equity of ¥110.6B reflects minimal leverage, well below typical manufacturing sector norms.
Cash and deposits increased ¥6.3B (+22.8%) year-over-year to ¥34.0B, indicating strong cash accumulation during the period. The cash build-up occurred alongside operating profit improvement from loss to ¥6.2B in operating income, suggesting that core business operations contributed to cash generation. Working capital movements reveal mixed dynamics, with trade receivables increasing ¥4.1B to ¥25.2B and inventories rising ¥4.3B to ¥21.1B, representing capital allocation to support revenue growth but also indicating extended collection and inventory cycles. Receivables turnover stands at approximately 110 days (¥25.2B / ¥83.0B × 365 × 0.75), exceeding the industry median of 85 days by 25 days and suggesting slower collection efficiency. Inventory turnover approximates 149 days (¥21.1B / ¥63.6B × 365 × 0.75), above the industry median of 112 days, indicating elevated inventory holdings relative to cost of sales. Trade payables of ¥16.4B provide natural financing, with payables turnover of approximately 115 days, well above the industry median of 56 days, reflecting extended payment terms or supplier credit utilization. Net working capital expansion absorbed cash during the period, with operating working capital turnover of approximately 174 days exceeding the industry median of 112 days by 62 days. Investment activities are evidenced by construction in progress increasing to ¥7.7B, representing 29.0% of total property, plant and equipment and indicating significant capital projects underway. Investment securities rose ¥2.2B to ¥17.2B, representing portfolio investments or strategic holdings. Financing structure remains conservative with long-term loans of ¥4.3B representing the primary interest-bearing debt. The cash coverage of short-term liabilities stands at 1.25 times, providing ample buffer. Comprehensive income of ¥8.0B exceeded net income of ¥6.0B by ¥2.0B, driven by valuation differences on securities of ¥1.9B and foreign exchange translation adjustments of ¥0.1B, indicating mark-to-market gains contributing to equity but not operating cash flow.
Ordinary income of ¥6.8B versus operating income of ¥6.2B shows a net non-operating contribution of approximately ¥0.6B, representing 9.7% enhancement to operating income. This comprises non-operating income of ¥0.9B offset partially by non-operating expenses of ¥0.2B, with the primary components being other non-operating income of ¥0.2B and foreign exchange losses of ¥0.2B. Non-operating income represents 1.1% of revenue, indicating limited reliance on financial activities for profitability. Extraordinary items totaled ¥0.8B in gains, primarily from gain on sale of assets of ¥0.1B and other one-time items, contributing 13.3% to net income. The presence of extraordinary gains indicates that ¥0.8B of the ¥6.0B net income derives from non-recurring sources, suggesting a normalized earnings level closer to ¥5.2B excluding these items. The effective tax rate of 22.1% (income tax expense ¥1.7B / profit before tax ¥7.7B) appears reasonable and suggests no material tax adjustments or deferrals distorting earnings. Comprehensive income exceeded net income by ¥2.0B due to valuation gains on securities and foreign exchange translation effects, indicating that ¥2.0B of equity accretion did not flow through cash-based earnings. While detailed operating cash flow statements are not provided for this quarterly period, the balance sheet analysis suggests earnings quality concerns related to working capital efficiency. The increase in receivables and inventories absorbing cash while revenues grow indicates that a portion of reported revenue growth has not yet converted to cash, creating a timing gap. The ratio of working capital changes to revenue growth approximates 67% (¥8.4B working capital increase / ¥12.4B revenue increase), suggesting that two-thirds of incremental sales are financing working capital expansion rather than generating free cash. This pattern warrants monitoring for sustainability, as sustained revenue growth with proportional working capital expansion would constrain cash conversion.
Full-year guidance anticipates revenue of ¥107.0B, operating income of ¥6.0B, ordinary income of ¥6.5B, and net income of ¥6.0B. The Q3 year-to-date cumulative results show revenue of ¥83.0B representing 77.6% progress versus full-year target, which exceeds the typical 75% milestone at the nine-month mark by 2.6 percentage points. Operating income of ¥6.2B already surpasses the full-year target of ¥6.0B by ¥0.2B, indicating Q3 cumulative achievement of 103.3% of the annual plan. This suggests either conservative initial guidance or stronger-than-expected Q1-Q3 performance, with the implied Q4 operating income guidance effectively at break-even or slight loss. Ordinary income progress of ¥6.8B represents 104.6% of the ¥6.5B full-year target, similarly indicating front-loaded profitability. Net income achievement of ¥6.0B reaches 100% of the full-year target, suggesting no additional net income expected in Q4 under the current guidance framework. The company disclosed guidance revision during this quarter, though specific changes are not detailed in the provided data. The forecast assumes EPS of ¥73.73 for the full year compared to Q3 year-to-date actual EPS of ¥74.12, implying potential dilution or modest Q4 loss per share. Annual dividend forecast of ¥5.00 appears conservative relative to the strong first nine months performance, with interim dividend already paid at ¥7.5. The divergence between strong Q3 cumulative results and conservative full-year guidance suggests potential caution regarding Q4 seasonality, project timing, or conservative scenario planning. Progress rates exceeding 100% for operating income, ordinary income, and net income indicate high probability of upward revision potential unless Q4 faces significant headwinds.
Annual dividend forecast stands at ¥5.00 per share for the full fiscal year, though the interim dividend already paid was ¥7.5 per share. The interim dividend of ¥7.5 combined with the forecast suggests total annual dividend distribution higher than the stated ¥5.00 forecast, requiring clarification of whether ¥5.00 represents year-end dividend or total annual amount. Based on the year-end forecast of ¥5.00 in addition to interim ¥7.5, implied total annual dividend would be ¥12.5 per share. Applying this to forecasted full-year EPS of ¥73.73, the payout ratio calculates to 17.0%, representing a conservative dividend policy with significant earnings retention. Against Q3 actual EPS of ¥74.12, the ¥12.5 total dividend implies payout ratio of 16.9%, confirming conservative distribution approach. At the forecasted annual dividend of ¥5.00 as stated, the payout ratio against forecast EPS of ¥73.73 would be 6.8%, which appears unusually low and may indicate interpretation discrepancy. Cash and deposits of ¥34.0B provide substantial dividend coverage, with total annual dividend outlay of approximately ¥1.1B (¥12.5 × 8,625 thousand shares) representing just 3.2% of cash reserves. No share buyback programs are disclosed in the current period data. The total return ratio matches the payout ratio given absence of buybacks, standing at approximately 17% using the ¥12.5 total dividend assumption. The dividend sustainability appears robust given strong cash position, return to profitability, and minimal debt obligations requiring service.
Working capital efficiency deterioration represents a high-likelihood, medium-to-high impact risk. Accounts receivable days of approximately 110 days exceed the industry median by 25 days, while inventory days of approximately 149 days exceed the median by 37 days, together resulting in operating working capital turnover of 174 days versus industry median of 112 days. This 62-day gap indicates that ¥14.2B of additional capital is tied up in working capital versus industry-typical levels (62 days × ¥83.0B / 365), representing potential cash opportunity cost. If working capital efficiency continues to deteriorate, cash generation will lag earnings growth, constraining financial flexibility and shareholder distributions despite strong reported profitability. The revenue growth of 17.5% accompanied by working capital absorption of 67% of incremental sales indicates structural inefficiency requiring management attention.
Construction in progress recovery risk presents medium likelihood and medium impact exposure. Construction in progress of ¥7.7B represents 29.0% of total property, plant and equipment and 5.3% of total assets, indicating significant capital committed to incomplete projects. The elevated CIP balance relative to completed fixed assets suggests either large-scale facility expansion or extended project timelines. If projects face delays, cost overruns, or demand shortfalls upon completion, the company faces impairment risk and delayed return on invested capital. The effective asset turnover on new capacity will determine whether the ¥7.7B investment generates sufficient returns to maintain or improve overall ROIC. With current total asset turnover at 0.574 matching industry median, the incremental returns on CIP assets must meet or exceed this level to avoid dilution of group-wide capital efficiency.
One-time gain dependency creates medium likelihood and medium impact risk to normalized earnings run-rate. Extraordinary income of ¥0.8B contributed 13.3% to reported net income of ¥6.0B, indicating that sustainable normalized earnings approximate ¥5.2B absent non-recurring items. The gap between ordinary income of ¥6.8B and operating income of ¥6.2B reflects ¥0.6B of non-operating items that may include some recurring financial income but also potentially volatile components. If Q4 lacks similar extraordinary gains, full-year results may fall short of current run-rate extrapolations despite strong Q3 performance. The comprehensive income including ¥1.9B of securities valuation gains that have not realized in cash presents additional volatility risk to book equity but not operating performance.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 5.5% slightly trails the industry median of 5.8% by 0.3 percentage points, placing the company near the median but with room for improvement through enhanced asset utilization or margin expansion. The DuPont components reveal that net profit margin of 7.3% exceeds the industry median of 6.5%, asset turnover of 0.574 matches the industry median of 0.56, while financial leverage of 1.31 falls well below the industry median of 1.53. This indicates the company achieves above-median profitability per sales unit and average capital efficiency, but maintains materially lower leverage than peers, constraining ROE relative to its operational performance. Operating margin of 7.5% trails the industry median of 8.9% by 1.4 percentage points, indicating the company operates in the lower half of the efficiency distribution within the manufacturing sector.
Financial Health: Equity ratio of 76.5% substantially exceeds the industry median of 63.8% by 12.7 percentage points, positioning the company in the upper quartile for financial stability and providing significant debt capacity for potential expansion or shareholder returns. Current ratio of 361.5% far exceeds the industry median of 287%, indicating exceptional short-term liquidity though potentially inefficient capital deployment. The minimal interest-bearing debt and strong cash position translate to negative net debt, contrasting with the industry median net debt / EBITDA of -1.11, confirming the company's position among the most conservative balance sheets in the sector.
Efficiency: Asset turnover of 0.574 matches the industry median of 0.56, indicating average capital intensity and utilization relative to manufacturing peers. However, operating working capital turnover of approximately 174 days significantly exceeds the industry median of 112 days by 62 days, revealing material inefficiency in working capital management. Receivables turnover of 110 days exceeds the industry median of 85 days by 25 days, inventory turnover of 149 days exceeds the median of 112 days by 37 days, while payables turnover of 115 days exceeds the median of 56 days by 59 days. The combined effect places the company among the slowest working capital converters in the industry, representing a competitive disadvantage in cash generation velocity.
Growth and Returns: Revenue growth of 17.5% substantially exceeds the industry median of 2.8%, positioning the company in the upper quartile for top-line expansion and indicating strong market demand or share gains. However, EPS growth comparison requires context given the prior period loss, with the company's turnaround from negative to positive EPS not directly comparable to the industry median growth of 9%. Return on assets of 4.2% exceeds the industry median of 3.4%, reflecting the company's above-median profitability offsetting average asset intensity. The company's Rule of 40 metric (revenue growth rate plus operating margin) approximates 25% (17.5% + 7.5%), exceeding the industry median of 12% and indicating a favorable growth-profitability balance relative to manufacturing sector norms.
(※ Industry: Manufacturing sector, Comparison: FY2025 Q3 median and interquartile range benchmarks, Source: Proprietary analysis)
Structural profitability recovery marks a critical inflection point, with the company achieving operating income turnaround from ¥-1.8B loss to ¥6.2B profit representing ¥8.0B improvement year-over-year. The gross margin expansion to 23.4% from prior 16.8% combined with operating margin reaching 7.5% from negative territory demonstrates fundamental operational improvement rather than purely revenue-driven leverage. FineChemical segment margin of 24.6% and operating income of ¥9.6B establishes this business as the core profit engine, contributing 67% of total segment profits. The consistency of improvement across all three segments with FlameRetardants segment profit rising ¥3.0B and HealthSupport growing ¥0.5B indicates broad-based rather than isolated recovery. Current profitability metrics position the company near industry median for ROE and ROA while exceeding median for net profit margin, suggesting the turnaround places the company in competitive standing with normalized performance potential for further improvement toward upper-quartile positioning.
Working capital efficiency deterioration emerges as the primary operational concern requiring management focus, with operating working capital cycle of 174 days exceeding industry median by 62 days and absorbing ¥14.2B of incremental capital relative to industry-efficient levels. The company's receivables collection of 110 days versus industry median 85 days indicates 25 days of excess credit extension, while inventory holding of 149 days versus median 112 days represents 37 days of excess stock. Despite extended payables of 115 days providing partial offset, the net working capital inefficiency constrains cash conversion with approximately 67% of revenue growth financing working capital expansion. This dynamic creates a divergence between strong reported earnings (net income ¥6.0B, EPS ¥74.12) and cash generation quality, as evidenced by receivables rising ¥4.1B and inventories increasing ¥4.3B during the period. Improvement in working capital velocity to industry-median levels would release approximately ¥14.2B of cash for alternative deployment while enhancing sustainable free cash flow generation. The working capital issue represents neither a near-term liquidity risk given ¥34.0B cash reserves nor a solvency concern given 76.5% equity ratio, but rather an efficiency drag limiting the company's capital productivity relative to operational performance.
Financial positioning provides substantial strategic flexibility with conservative capital structure offering multiple deployment options. Equity ratio of 76.5% exceeding industry median 63.8% combined with minimal leverage (debt-to-equity ratio of 0.04) positions the company with approximately ¥15-20B of potential debt capacity while maintaining investment-grade metrics. Current cash of ¥34.0B exceeds short-term liabilities of ¥27.1B by ¥6.9B, providing immediate liquidity buffer, while total liquidity sources could support significant acquisition or capital investment. Construction in progress of ¥7.7B signals ongoing capacity expansion with implied completion providing additional revenue-generating assets in future periods. The conservative dividend payout ratio of approximately 17% (assuming ¥12.5 annual dividend) retains 83% of earnings for reinvestment or future distribution increases. Management faces capital allocation decisions balancing organic growth investment (CIP projects), working capital optimization, potential M&A given strong currency position, and progressive shareholder returns given improving profitability. The company's strong cash generation potential once working capital efficiency improves could support dividend growth trajectory while maintaining investment capacity.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.